Posted on September 19, 2019 by Sitemaster
A newly published article in Lancet Oncology has suggested that “taxane–platinum combinations have a clinically beneficial role in advanced prostate cancer”. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, carboplatin, castration-resistant, mCRPC, metastatic | 2 Comments »
Posted on October 5, 2015 by Sitemaster
There is an increasing level of evidence about our ability to identify small and carefully selected groups of patients with advanced disease who, despite the fact that they no longer respond to standard treatments, may respond well to other forms of therapy. … READ MORE …
Filed under: Uncategorized | Tagged: carboplatin, castration-resistant, chemotherapy, everolimus, individualized, metastatic, outcome, personalized | 5 Comments »
Posted on July 18, 2011 by Sitemaster
The results of the French Genito-Urinary Tumor Group (GETUG) P01 trial — a Phase II study of carboplatin and etoposide in men with progressive metastatic castration-resistant prostate cancer (mCRPC) — have shown that this form of combination chemotherapy has limited efficacy and an unacceptably high toxicity in men with late stage prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: carboplatin, castration-rsistant, etopside, mCRPC, metastasis, neuroendocine | Leave a comment »
Posted on September 2, 2009 by Sitemaster
Today’s news reports address:
- Barbers as prostate risk educators in the black community
- The need for a Phase III trial of docetaxel + carboplatin in CRPC … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: barber, carboplatin, castration-resistant prostate cancer, CRPC, docetaxel, educator, risk | Leave a comment »
Posted on February 24, 2009 by Sitemaster
We have dealt separately with an article on the way in which surgical technique appears to affect the likelihood of positive surgical margins after robot-assisted laparoscopic prostatectomy (RALP). Other reports today cover:
- Whether multifocal tumors are “riskier” that single prostate cancer tumors
- The role of n-3 fatty acids in prevention of selected cancers (including prostate cancer)
- Lycopene in prevention and treatment of prostate cancer
- Serum cholesterol levels and prostate cancer
- Different forms of imaging for prostate cancer localization during EBRT
- Carboplatin + etopside chemotherapy in late-stage metastatic disease … READ MORE …
Filed under: Management, Prevention, Risk, Treatment, Uncategorized | Tagged: carboplatin, cholesterol, etopside, localization, lycopene, multifocal, n-3 fatty acids, unifocal | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 